Efficacy and safety profile of anti-interleukin-1 treatment in Behçet’s disease: a multicenter retrospective study

2015 ◽  
Vol 35 (5) ◽  
pp. 1281-1286 ◽  
Author(s):  
Giacomo Emmi ◽  
Rosaria Talarico ◽  
Giuseppe Lopalco ◽  
Rolando Cimaz ◽  
Fabrizio Cantini ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Behçet’S Disease ◽  
Safety Profile ◽  
Behcet’S Disease ◽  
Behçet's Disease ◽  
Interleukin 1 ◽  
Efficacy And Safety ◽  
Behcet's Disease

Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease

2015 ◽  
Vol 14 (1) ◽  
pp. 1-9 ◽  
Author(s):  
Luca Cantarini ◽  
Giuseppe Lopalco ◽  
Francesco Caso ◽  
Luisa Costa ◽  
Florenzo Iannone ◽  
...  
Keyword(s):  
Behçet’S Disease ◽  
Safety Profile ◽  
Behcet’S Disease ◽  
Behçet's Disease ◽  
Interleukin 1 ◽  
Behcet's Disease ◽  
Blocking Agents

scholarly journals AB0531 GOLIMUMAB IN THE TREATMENT OF SEVERE AND/OR REFRACTORY VASCULO-BEHÇET’S DISEASE: A SINGLE-CENTRE EXPERIENCE IN CHINA

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1562.1-1563
Author(s):  
L. Sun ◽  
J. Liu ◽  
W. Zheng
Keyword(s):  
Aortic Regurgitation ◽  
Behçet’S Disease ◽  
Behcet’S Disease ◽  
Behçet's Disease ◽  
High Dose ◽  
Efficacy And Safety ◽  
Behcet's Disease ◽  
Severe Aortic Regurgitation ◽  
Tnf Α

Background:Vascular involvement is one of the leading causes of mortality and morbidity in Behcet’s Disease (BD)1. Surgical treatments are difficult for Vaculo-BD (VBD) patients due to the high risk of serious postoperative complications without effective and promptly perioperative immunotherapy2, 3. Anti-tumor necrosis factor alpha (TNF-α) therapy has been reported as a potential treatment in severe VBD, e.g. infliximab (IFX) and adalimumab (ADA). However, only few case reports are available regarding the fully humanized monoclonal antibody to TNF-α, golimumab (GOL), in the management of VBD4.Objectives:The objective of this study was to report the efficacy and safety of GOL for the treatment of severe and/or refractory VBD.Methods:We retrospectively analyzed the efficacy and safety profile of patients with severe and/or refractory VBD treated with GOL in our medical center between 2018 to 2020.Results:Nine VBD patients (8 male and 1 female) were enrolled, with a mean age and median course of 37±8.6 years and 72 months (range 12 to 300), respectively. Cardiac involvements (severe aortic regurgitation secondary to BD) were presented in 7 patients, including 2 patients with post-operative paravalvular leakage (PVL) after aortic valve replacement surgery. Multiple vascular lesions were documented in the other 2 patients, including one patient with life-threatening multiple pulmonary aneurysms, pulmonary thromboembolism and recurrent deep vein thrombosis, and another patient with abdominal aortic pseudoaneurysm and multiple artery stenosis and occlusion. Prior to GOL therapy, all patients experienced disease progression despite high-dose glucocorticoids combined with multiple immunosuppressants. Moreover, seven patients required effective and fast control of inflammation and a decrease of glucocorticoid dose during the perioperative period. They were treated with GOL, 50mg every 4 weeks, in combination with background low-or medium-dose glucocorticoids and immunosuppressants, for a median of 6 (range 3-15) months. After a mean duration of follow-up of 10 (range 2-6) months, all patients achieved improvement both in clinical symptoms and serum inflammation markers. The ESR level [4.88±4.94 mm/h vs 31.13±31.78mm/h, P<0.01] and CRP level [1.9 (0.11-3.73)mg/L vs 24.3 (0.4-85.57)mg/L, P<0.01] significantly decreased. The dosage of glucocorticoid[10 (0-15) vs 40 (0-100)mg/d, P<0.01] effectively tapered, indicating a potential steroid-sparing effect. No newly-onset aneurysm and recurrent venous thrombosis were observed. Also, one patient had a marked reduction in size and number of pulmonary aneurysms. No post-operative PVL was observed in the five patients after Bentall operation with a median follow-up of 10 months. One patient with severe aortic regurgitation remained stable and without surgical intervention with the treatment of GOL for 16 months. No severe complication occurred in one patient after underwent endovascular repair of abdominal aorta for 8 months. GOL was well-tolerated, and no serious adverse event was observed.Conclusion:Our results suggested that GOL is safe and effective for the treatment of patients with severe and / or refractory VBD. Further controlled studies are warranted to confirm the therapeutic potential of GOL in VBD patients.Disclosure of Interests:None declared

scholarly journals Chlorambucil and cyclosporine A in Brazilian patients with Behçet's disease uveitis: a retrospective study

2010 ◽  
Vol 73 (1) ◽  
pp. 40-46 ◽  
Author(s):  
Juliana Marques Zaghetto ◽  
Mirian Mina Yamamoto ◽  
Murilo Barreto Souza ◽  
Felipe Theodoro Bezerra Gaspar Carv Silva ◽  
Carlos Eduardo Hirata ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Behçet’S Disease ◽  
Cyclosporine A ◽  
Behcet’S Disease ◽  
Behçet's Disease ◽  
Behcet's Disease

scholarly journals Efficacy and safety of systemic recombinant interferon‐alpha in Behcet's disease

1998 ◽  
Vol 243 (5) ◽  
pp. 367-372 ◽  
Author(s):  
Georgiou ◽  
Monastirli ◽  
Pasmatzi ◽  
Gartaganis ◽  
Goerz ◽  
...  
Keyword(s):  
Behçet’S Disease ◽  
Interferon Alpha ◽  
Behcet’S Disease ◽  
Behçet's Disease ◽  
Efficacy And Safety ◽  
Recombinant Interferon ◽  
Behcet's Disease ◽  
Recombinant Interferon Alpha

Efficacy and safety of biological therapy compared to synthetic immunomodulatory drugs or placebo in the treatment of Behçet’s disease associated uveitis: a systematic review

2018 ◽  
Vol 39 (1) ◽  
pp. 47-58 ◽  
Author(s):  
Ana Urruticoechea-Arana ◽  
Tatiana Cobo-Ibáñez ◽  
Virginia Villaverde-García ◽  
Montserrat Santos Gómez ◽  
Estíbaliz Loza ◽  
...  
Keyword(s):  
Systematic Review ◽  
Behçet’S Disease ◽  
Behcet’S Disease ◽  
Biological Therapy ◽  
Behçet's Disease ◽  
Immunomodulatory Drugs ◽  
Efficacy And Safety ◽  
Behcet's Disease

scholarly journals Investigation of the role of interleukin-1 receptor antagonist VNTR variant on the Behçet’s disease

2018 ◽  
Vol 5 (1) ◽  
pp. 27-31
Author(s):  
Gul Dursun ◽  
Ayse Feyda Nursal ◽  
Helin Deniz Demir ◽  
Nevin Karakus ◽  
Osman Demir ◽  
...  
Keyword(s):  
Receptor Antagonist ◽  
Behçet’S Disease ◽  
Behcet’S Disease ◽  
Behçet's Disease ◽  
Interleukin 1 ◽  
Behcet's Disease ◽  
Interleukin 1 Receptor Antagonist

scholarly journals Long-term efficacy and safety of anakinra in a patient with Behçet's disease and concomitant tuberculosis infection

2016 ◽  
Vol 56 (2) ◽  
pp. 218-220 ◽  
Author(s):  
Giacomo Emmi ◽  
Elena Silvestri ◽  
Danilo Squatrito ◽  
Antonio Vitale ◽  
Daniela Bacherini ◽  
...  
Keyword(s):  
Behçet’S Disease ◽  
Behcet’S Disease ◽  
Behçet's Disease ◽  
Tuberculosis Infection ◽  
Efficacy And Safety ◽  
Behcet's Disease ◽  
Term Efficacy

Long-term efficacy and safety of golimumab in the treatment of multirefractory Behçet’s disease

2017 ◽  
Vol 36 (9) ◽  
pp. 2063-2069 ◽  
Author(s):  
Antonio Vitale ◽  
Giacomo Emmi ◽  
Giuseppe Lopalco ◽  
Claudia Fabiani ◽  
Stefano Gentileschi ◽  
...  
Keyword(s):  
Behçet’S Disease ◽  
Behcet’S Disease ◽  
Behçet's Disease ◽  
Efficacy And Safety ◽  
Behcet's Disease ◽  
Term Efficacy

Inhibition of Interleukin-1 by Canakinumab as a Successful Mono-Drug Strategy for the Treatment of Refractory Behçet's Disease: A Case Series

Dermatology ◽  
2014 ◽  
Vol 228 (3) ◽  
pp. 211-214 ◽  
Author(s):  
Antonio Vitale ◽  
Donato Rigante ◽  
Francesco Caso ◽  
Maria Giuseppina Brizi ◽  
Mauro Galeazzi ◽  
...  
Keyword(s):  
Behçet’S Disease ◽  
Behcet’S Disease ◽  
Behçet's Disease ◽  
Interleukin 1 ◽  
Case Series ◽  
Behcet's Disease
Sign in / Sign up

Export Citation Format

Share Document